A Comparison Of Oral Vs Intravenous Tranexamic Acid In Patients Undergoing Staggered Bilateral Total Knee Arthroplasty

Document Type : RESEARCH PAPER

Authors

1 Electricwala Hospital, Pleasant Park D Building, Pune, Maharashtra, India

2 Essence Medical Centre, Westwinds, Westwinds Dr. NE, Calgary, Alberta, Canada

Abstract

Background: All previous studies comparing the blood sparing efficacy oral and intravenous tranexamic acid (TXA) in 
total knee arthroplasty have involved two or more patient cohorts, outcomes of which may be limited by inter-individual 
variability in human drug response. The purpose of this study was to evaluate if both oral and intravenous preparations 
of TXA are equivalent at reducing blood loss in the same patients undergoing staggered bilateral total knee arthroplasty.
Methods: 40 patients undergoing staggered bilateral total knee replacement were recruited. They received 2 g of oral 
TXA 2 hours preoperatively for the first knee and 1 g of bolus intravenous TXA 15 minutes before skin incision for the 
second knee. 7 patients were excluded for protocol deviation, leaving 33 participants for the study. The second knee 
was operated within 5-6 days of the first knee. The primary outcome was reduction in hemoglobin. Equivalence was 
tested with a two one-sided test (TOST) and a P < 0.05 indicated equivalence between oral and intravenous modes of 
TXA administration. 
Results: The mean reduction in hemoglobin was similar between oral and intravenous mode of TXA administration 
(2.18 and 2.16 g/dl respectively, P<0.0001, equivalence). There was no significant difference in the total hemoglobin 
loss and total red blood cell volume loss {(104 and 102 g, P=0.86) and (865 and 863 ml, P=0.53) respectively}. 
Conclusion: Oral and intra venous TXA have equal blood sparing properties in patients undergoing staggered bilateral 
total knee arthroplasty.
Level of evidence: II

Keywords


1. Ponnusamy KE, Kim TJ, Khanuja HS. Perioperative 
blood transfusions in orthopaedic surgery. J Bone 
Joint Surg Am. 2014; 96(21):1836-44.
2. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, 
Trout R, et al. Effect of anaemia and cardiovascular 
disease on surgical mortality and morbidity. The 
Lancet. 1996; 348(9034):1055-60.
3. Levy JH, Koster A, Quinones QJ, Milling TJ, Key 
NS. Antifibrinolytic therapy and perioperative 
considerations. Anesthesiology. 2018; 128(3):657-70.
4. Xie J, Ma J, Yue C, Kang P, Pei F. Combined use of 
intravenous and topical tranexamic acid following 
cementless total hip arthroplasty: a randomised 
clinical trial. Hip International. 2016; 26(1):36-42.
5. Sridharan K, Sivaramakrishnan G. Tranexamic acid 
in total hip arthroplasty: a recursive cumulative 
meta-analysis of randomized controlled trials 
and assessment of publication bias. Journal of 
orthopaedics. 2017; 14(3):323-8.
6. Kozek-Langenecker SA, Ahmed AB, Afshari A, 
Albaladejo P, Aldecoa C, Barauskas G, et al. Management 
of severe perioperative bleeding: guidelines from the 
European Society of Anaesthesiology: first update 
2016. European Journal of Anaesthesiology| EJA. 
2017; 34(6):332-95.
7. Nishihara S, Hamada M. Does tranexamic acid 
alter the risk of thromboembolism after total hip 
arthroplasty in the absence of routine chemical 
thromboprophylaxis? The Bone & Joint Journal. 2015; 
97(4):458-62.
8. Fillingham YA, Kayupov E, Plummer DR, Moric M, 
Gerlinger TL, Della Valle CJ. The James A. Rand Young 
Investigator’s Award: a randomized controlled trial 
of oral and intravenous tranexamic acid in total knee 
arthroplasty: the same efficacy at lower cost? The 
Journal of arthroplasty. 2016; 31(9):26-30.
9. Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral 
vs intravenous vs topical tranexamic acid in primary 
hip arthroplasty: a prospective, randomized, doubleblind, controlled study. The Journal of arthroplasty. 
2018; 33(3):786-93.
10.Turner RM, Park BK, Pirmohamed M. Parsing 
interindividual drug variability: an emerging role 
for systems pharmacology. Wiley Interdisciplinary 
Reviews: Systems Biology and Medicine. 2015; 
7(4):221-41.
11.Sweeney GD. Variability in the human drug response. 
Thrombosis Research. 1983; 29:3-15.
12.Gurunathan U. Staggered bilateral knee arthroplasty: 
good or bad? Anesthesiology. 2010; 113(1):256-8.
13.Morris JK, Fincham BM. Intermittent pneumatic 
compression for venous thromboembolism 
prophylaxis in total knee arthroplasty. Orthopedics. 
2012; 35(12):e1716-21.
14.Crawford DA, Andrews RL, Morris MJ, Hurst JM, 
Lombardi Jr AV, Berend KR. Ambulatory portable 
pneumatic compression device as part of a 
multimodal aspirin-based approach in prevention of 
venous thromboembolism in outpatient total knee 
arthroplasty. Arthroplasty today. 2020; 6(3):378-80.
15.Algadiem EA, Aleisa AA, Alsubaie HI, Buhlaiqah NR, 
Algadeeb JB, Alsneini HA. Blood loss estimation using 
gauze visual analogue. Trauma monthly. 2016; 21(2).
16.Gao FQ, Li ZJ, Zhang K, Sun W, Zhang H. Four methods 
for calculating blood-loss after total knee arthroplasty. 
Chinese medical journal. 2015; 128(21):2856-60. 17.Jansen AJ, Andreica S, Claeys M, D’haese J, Camu F, 
Jochmans K. Use of tranexamic acid for an effective 
blood conservation strategy after total knee 
arthroplasty. British journal of Anaesthesia. 1999; 
83(4):596-601.
18.Benoni G, Fredin HA. Fibrinolytic inhibition with 
tranexamic acid reduces blood loss and blood 
transfusion after knee arthroplasty: a prospective, 
randomised, double-blind study of 86 patients. The 
Journal of bone and joint surgery. British volume. 
1996; 78(3):434-40.
19.Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, 
Reed MR. Oral versus intravenous tranexamic acid 
in enhanced-recovery primary total hip and knee 
replacement: results of 3000 procedures. The Bone & 
Joint Journal. 2013; 95(11):1556-61.
20.Jules-Elysee KM, Tseng A, Sculco TP, Baaklini LR, 
McLawhorn AS, Pickard AJ, et al. Comparison of 
topical and intravenous tranexamic acid for total 
knee replacement: a randomized double-blinded 
controlled study of effects on tranexamic acid levels 
and thrombogenic and inflammatory marker levels. 
The Journal of bone and joint surgery. American 
volume. 2019; 101(23):2120.
21.Guo P, He Z, Wang Y, Gao F, Sun W, Guo W, et al. Efficacy 
and safety of oral tranexamic acid in total knee 
arthroplasty: a systematic review and meta-analysis. 
Medicine. 2018; 97(18).
22.Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, 
Shores P, Mullen K, et al. The efficacy of tranexamic acid 
in total knee arthroplasty: a network meta-analysis. 
The Journal of arthroplasty. 2018; 33(10):3090-8.
23.Xiong H, Liu Y, Zeng Y, Wu Y, Shen B. The efficacy and 
safety of combined administration of intravenous 
and topical tranexamic acid in primary total knee 
arthroplasty: a meta-analysis of randomized 
controlled trials. BMC musculoskeletal disorders. 
2018; 19(1):1-1.
24.Wang D, Luo ZY, Yu ZP, Liu LX, Chen C, Meng WK, et 
al. The antifibrinolytic and anti‐inflammatory effects 
of multiple doses of oral tranexamic acid in total 
knee arthroplasty patients: a randomized controlled 
trial. Journal of Thrombosis and Haemostasis. 2018; 
16(12):2442-53.
Volume 10, Issue 3
March 2022
Pages 261-266
  • Receive Date: 14 June 2020
  • Revise Date: 18 July 2021
  • Accept Date: 03 August 2021
  • First Publish Date: 30 August 2021